Compound Azintamide Enteric-coated Tablets, Pancreatin supplement with simethicone, effectively promote choleretic, quickly eliminate abdominal distension, effectively relieve indigestion symptoms such as loss of appetite, abdominal discomfort, early satiety, belching, fatty stool, chemical indigestion, etc.

CSL Behring is one of the largest import suppliers in China's human albumin market. Baheal has collaborated with CSL Behring since 2018 and remains a key partner for CSL Behring in China. Human albumin is a life-saving product primarily used to treat shock caused by hemorrhagic trauma or burns, as well as for the prevention and treatment of hypoalbuminemia. Due to factors such as stringent market regulation, increased clinical demand, and limited plasma supply, China's human albumin market has consistently faced a supply shortage.

An US dietary supplements brand, specialized in the development and production of natural, organic, and high-potency dietary supplements.

Micro-needle eye mask, applying the "transdermal drug delivery technology” originated from a key invention of a Japanese medical laboratory, enabling users to have medical-level care at home. Medical evidence shows safe and effective release of worries about trauma, pain, escharotic and reconstruction. With simple ingredients, high efficacy and 40+ patents, it effectively relieves the symptoms of dark circles, fine lines around the eyes, etc.

Bi Bai Ke originates from the Qing Dynasty imperial prescription “Wan Ying Ding,” a formula for clearing heat and detoxifying the body. It uses natural bear bile powder as its primary ingredient, with each tablet containing 11.1mg of bear bile powder. It is formulated with authentic herbs such as wine-processed rhubarb and Coptis chinensis, following a rigorous and well-balanced formulation. It is specifically used for various symptoms of “heat” in the body, offering unique therapeutic effects.

Mainly invested by Baheal and is a leading artificial heart R&D enterprise in China, BRIOHEALTH SOLUTIONS has developed the next-generation fully magnetically levitated LVAD with autonomous IP. Currently, the product CIFU® is the world-class ventricular assist device, especially in terms of hemocompatibility, implantation invasiveness and operational reliability. Until the end of 2025, the implantation operations of this product have undergone in more than 80 of China's top cardiovascular hospitals and has benefited more than 670 end-stage heart failure patients. The first patient implanted with our product had successfully survived for seven years and then underwent a heart transplant. CIFU® has significantly improved survival rates for patients with end-stage heart failure.

As China's first active implantable medical device approved by FDA for clinical trials, BrioVAD® has been implanted in over 100 cases across 22 U.S. clinical centers until the end of 2025. It has not only gained recognition and support from top medical centers in the U.S., but also secured Medicare coverage, with each implant covered by $220,000 in Medicare funding. This clinical trial will expand to 60 U.S. clinical centers and is expected to include 800 implantation operations.

ZAP-X AI radiosurgery robot is dedicated to intracranial tumors and lesions and was specifically developed by the world's leading neurosurgeons, John R. Adler. Through end-to-end AI empowerment, this device establishes a closed-loop system covering from intelligent radiotherapy plans to precise performance. It delivers an innovative solution about dual monitoring and validation system for real-time imaging and dose, enabling highly efficient and precise targeting of the treatment area while protecting surrounding tissue. This approach achieves a double improvement in treatment efficiency and quality. Currently, this device has obtained market approval in 26 countries and regions, including China, and has completed over 5,000 clinical treatments.

Enrolled in China National Reimbursement Drug List (NRDL) category B list, level I medical evidence. First anti-hepatic fibrosis therapeutic drug recommended in six Major Guidelines or Consensuses. First FDA Phase II clinical trial completed Chinese proprietary therapeutic drug for hepatopathy. Substantial clinical evidence shows the efficacy of preventing and treating hepatic fibrosis, liver cirrhosis.

Utidelone Injection is a tumor chemotherapy drug and a Class I innovative drug developed by Huahai Zhongtian (China's first publicly listed synthetic biology pharmaceutical company). (First approved indication) It is indicated for the treatment of recurrent or metastatic advanced breast cancer. Compared to taxane drugs, it offers superior safety, enhanced efficacy, reduced susceptibility to drug resistance, and the ability to cross the blood-brain barrier.